Text S1: Cohort specific methods and acknowledgements
cohort was supported by grant U01 HG004729 from the National Human Genome Research Institute.
FinnTwin12 and FinnTwin16
Study description: Analyses were based on samples from unrelated individuals from the when the twins were 17, 18.5, approximately 25 years, and most recently at an average age of 34 years. For both the FT12 and FT16, the baseline and follow-up assessments included surveys of smoking habits and other health-related variables. In addition, in wave 4 blood samples for DNA extraction and biochemistry analyses were taken from all twins during a visit to the twin research clinic in Helsinki (Finland). Altogether 145 subjects were included in the GWAS discovery phase, with genome-wide genotype data generated with the Illumina Human670-QuadCustom BeadChip (Illumina, Inc., San Diego, CA, USA). In the replication phase 135 additional subjects were included, with genotype data for the top loci extracted from genome-wide genotype data generated with the Illumina HumanCoreExome-12v1-0
BeadChip and imputed according to the same protocol as for the discovery sample.
Data collection and analysis were approved by the ethics committees of the Department of Public Health of the University of Helsinki, the Helsinki and Uusimaa Hospital District and the IRB of Indiana University. Written informed consent was obtained from all participating twins.
Cotinine assessment: All biological samples were stored at -80°C at the National Institute for Health and Welfare. Serum samples were sent for cotinine measurement to University of Toronto (Dr. Rachel Tyndale). Samples were assessed by LCMS as previously described 5 .
Acknowledgements: The study has been supported by ENGAGE -European Network for invited to fill in an extensive baseline questionnaire (n = 7,993, 67% response rate) and to attend a locally organized health examination in which blood samples were taken (all regions but Lapland). After the baseline study, a self-administered questionnaire with detailed smoking history was given to individuals who had stated during the first part of the study that they had smoked at least 100 cigarettes during their lifetime (regions 1-3), or that they were current smokers (regions 4 and 5) (n = 1,992). Completed questionnaires were returned by mail, with one reminder. The number of participants in the smoking sub-study was 1,746 (91% response rate). Plasma cotinine was analyzed for those who identified themselves as daily smokers during the main FINRISK data collection and responded to the tobaccospecific questionnaire 7 .
FINRISK 1992 and FINRISK2007
Altogether 218 subjects from FINRISK 1992 and FINRISK 2007 were included in the GWAS discovery phase, with genome-wide genotype data generated with the Illumina HumanOmniExpress BeadChip (Illumina, Inc., San Diego, CA, USA). These samples belong to the Predict-CVD sub-cohort, which is a random subset of the whole FINRISK cohort, and has been previously described by Ganna and colleagues 8 . The Predict CVD -sample is enriched for individuals with a diagnosed cardiovascular event (coronary heart disease and/or ischemic stroke). The FINRISK studies were approved by the Ethical Committee of the Hospital District of Helsinki and Uusimaa. All the surveys were conducted according to the ethical rules of the National Public Health Institute, and the investigations were performed in accordance with the Declaration of Helsinki. All participants gave their written informed consent prior to participation in the study.
Cotinine assessment: Plasma cotinine from fasting blood samples was analysed with a gas chromatograph-mass spectrometer (GC-MS) at the National Institute for Health and Welfare, Helsinki, Finland as previously described in detail 6, 7 .
Acknowledgements: FINRISK has been primarily funded by budgetary funds of THL Thus, the FHS has evolved into a prospective, community-based, three generation family study. The FHS is a joint project of the National Heart, Lung and Blood Institute and Boston University. Part of the FHS subjects participated in a plasma metabolite sub-study. Data used in our study were extracted from this metabolite profiling study. 
GenMets/Health2000
Study description: The Health2000 study is a nationally representative sample of adult Finnish population, which includes a total of 8,028 subjects aged 30 or over. They were invited for an in-person study during which a blood sample was taken for cotinine measures and for DNA extraction. A detailed smoking history as described by Keskitalo and colleagues 10 was obtained. Altogether 485 subjects from GenMets were included in the GWAS discovery phase, with genome-wide genotype data generated with the Human610-Quad BeadChip (Illumina, Inc., San Diego, CA, USA). All participants gave written informed consent, and the study was approved by the Ethics Committee for Epidemiology and Public
Health of the Hospital District of Helsinki and Uusimaa, Finland.
Cotinine assessment: The cotinine concentration (ng/ml) was determined from the serum using liquid-phase radioimmunoassay methodology (Nicotine Metabolite DOUBLE ANTIBODY kit, Diagnostic Products Corporation, Los Angeles, CA, USA). Funding for SHARe genotyping was provided by NHLBI Contract N02-HL-64278.
Acknowledgements: GENMETS is
Genotyping was performed at Affymetrix (Santa Clara, California, USA) and the Broad Institute of Harvard and MIT (Boston, Massachusetts, USA) using the Affymetric GenomeWide Human SNP Array 6.0. Funding support for the Lung CT dataset was provided by grant HL077612-05A1.
NESDA
Study description: The Netherlands Study of Depression and Anxiety (NESDA) is an ongoing cohort study into the long-term course and consequences of depressive and anxiety disorders. A description of the study rationale, design and methods is given elsewhere 12 .
Briefly, in 2004 2,007 participants aged 18-65 years were recruited from the community (19%), general practice (54%) and secondary mental health care (27%). A total of 2,981 participants were included, consisting of persons with a current or past depressive and/or anxiety disorder and healthy controls. The research protocol was approved by the ethical committee of participating universities, and all respondents provided written informed consent.
Cotinine assessment: Fasting blood samples of NESDA participants were collected in each of the participating centers and kept frozen at -80 Celsius degrees. Cotinine concentrations were determined in the laboratory (Good Biomarker Sciences, Leiden, the Netherlands), and were assessed in blood plasma by solid phase competitive ELISA (Cotinine Direct ELISA kit, cat.
no: CO096D, Calbiotech, CA, USA) according to the manufacturer's instructions. The detection limit was 1 ng/ml. Intra-and inter-assay coefficients of variation for values >2 ng/ml were >20% and >15%, respectively. Genotyping was funded in part by grants from the National Institutes of Health (4R37DA018673-06, RC2 MH089951).
TwinsUK
Study description: Study subjects were twins enrolled in the TwinsUK registry, a national register of adult twins. Twins were recruited as volunteers by successive media campaigns without selecting for particular diseases or traits 17 . In this study we analysed data from 674
female twins who cotinine data available. The study was approved by St. Thomas' Hospital
Research Ethics Committee, and all twins provided informed written consent.
Cotinine assessment: Cotinine levels in TwinsUK were measured using a non-targeted mass spec-based metabolomic profiling using the Metabolon platform, as described previously 18 .
Metabolomic profiling was done in three batches. The raw cotinine levels were mediannormalised (dividing each cotinine concentration by the day cotinine median), then inverse normalised as the metabolite concentration was not normally distributed. To measure the correlation between Metabolon platform and LCMS method described in 5 , 12 samples were analysed with both methods. Cotinine assessment: Serum samples were sent for cotinine measurement to University of Toronto (Dr. Rachel Tyndale). Samples were assessed by LCMS as previously described 5 .
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